Intermediate stage Hodgkin's disease: Preliminary results on 210 patients treated with four ABVD chemotherapy cycles plus extended versus involved field radiotherapy

Anticancer Research

Volumn 24, Issue 6, 2004, Pages 4045-4050

  Anselmo, A P ^a   Cavalieri, E ^a   Osti, P M ^a   Cantonetti, M ^b   De Sanctis, Vitaliana ^a,c   Alfo, M ^a   Amadori, S ^b   Enrici, R Maurizi ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b Ematologia di Tor Vergata   (Italy)

^c NONE   (Italy)

Author keywords

Extended field radiotherapy; Hodgkin's disease; Intermediate stage HD; Involved field radiotherapy; Radiotherapy

Indexed keywords

BLEOMYCIN; DACARBAZINE; DOXORUBICIN; VINBLASTINE; ABVD PROTOCOL; ANTINEOPLASTIC AGENT;

ACUTE TOXICITY; ADOLESCENT; ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER RELAPSE; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; EXTENDED FIELD RADIOTHERAPY; FEMALE; FOLLOW UP; HODGKIN DISEASE; HUMAN; INTERMETHOD COMPARISON; INVOLVED FIELD RADIOTHERAPY; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RADIATION DOSE; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; CANCER STAGING; COMPARATIVE STUDY; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PATHOLOGY;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLEOMYCIN; COMBINED MODALITY THERAPY; DACARBAZINE; DOXORUBICIN; FEMALE; HODGKIN DISEASE; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; RADIOTHERAPY DOSAGE; RISK FACTORS; VINBLASTINE;

EID: 14944342755     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Loeffler M, Brosteanu O and Hasenclever D: Meta-analysis of chemotherapy versus combined modality treatment trials in Hodgkin's disease. J Clin Oncol 16(3): 818-829, 1998.
2. Anselmo AP, Bove MT, Cartoni C et al: Combined modality (ABVD plus radiotherapy) versus radiotherapy in the management of early stage (IIA) Hodgkin's disease with mediastinal involvement. Haematologica 77: 177-9, 1977.
3. Longo LD, Glanstein E and Duffey PL: Radiation therapy versus combination chemotherapy in the treatment of early stage Hodgkin's disease: seven years results of a prospective randomised trial. J Clin Oncol 9: 906-917, 1991.
4. Anselmo AP, Cantonetti M, Proia S, Cartoni C, Bellesi M and Maurizi Enrici R: Involved field versus extended field radiotherapy after ABVD chemotherapy in intermediate stage HD. Preliminary results. Ann Oncol 7(3): 112, 1996.
5. Engert A, Schilller P, Josting A, Herrmann R, Koch P, Sieber M, Boissevain F, de Wit M, Mezger J, Dumke E, Willich N, Muller RP, Schmidt BF, Renner H, Muller-Hermelink HK, Pfistne R, Wolf J, Hasenclever D, Loffler M and Diehl V: Involved field radiotherapy is equally effective and less toxic compared with extended field radiotherapy after four cycles of chemotherapy in patients with early-stage unfavourable Hodgkin's lymphoma: Results of the HD8 trial of the German Hodgkin's Lymphoma Study Group. J Clin Oncol 21(19): 3601-3608, 2003.
6. Hryniuk W and Goodyear M: The calculation of received dose intensity. J Clin Oncol 8: 1935-1937, 1990
7. Peto R and Peto J: Asymptotically efficient rank invariant test procedures. Stat Soc 135: 185-206, 1972.
8. Amemiya T: Tobit models: a survey. J Econometrics 24: 3-61, 1984.
9. Heckman J: The common structure of statistical models of truncation, sample, selection and limited dependent variables, and simple estimator for such models. Ann Econo Soc Measure 5: 475-492, 1976.
10. Davidson R and Mackinnon JG: Estimation and Inference in Econometrics. Oxford University Press, Oxford, 1993.
11. Kenrdrith M and Ananta M: Hodgkin's disease: long-term effects of therapy. Med Paediat Oncol 14: 88-96, 1986.
12. Kaldor JM, Day NE and Clarke EA: Leukemia following Hodgkin's disease. N Engl J Med 332: 7-13, 1990.
13. Papa G, Mauro FR, Anselmo AP et al: Acute leukaemia in patients treated for Hodgkin's disease. Br J Haematol 58: 43-52, 1984.
14. Van Leeuwen FE, Chorus AMJ and Van den Belt-Dusebout AW: Leukemia risk following Hodgkin's disease: relation to cumulative dose of alkylating agents, treatment with teniposide combinations, number of episodes of chemotherapy, and bone marrow damage. J Clin Oncol 12: 1063-1073, 1994.
15. Abrahamsen JF, Andersen A and Hannisdal E: Second malignancies after treatment of Hodgkin's disease: the influence of treatment, follow-up time, and age. J Clin Oncol 11: 255-261, 1993.
16. Cimino G, Papa G and Tura S: Second primary cancer following Hodgkin's disease: update results of an Italian multicentric study. J Clin Oncol 9: 432-437, 1991.
17. Rodriguez MA, Fuller LM and Zimmermann SO: Hodgkin's disease: study of treatment intensities and incidences of second malignancies. Ann Oncol 4: 125-131, 1993.
18. Maurizi Enrici R, Anselmo AP, Osti MF, Sbarbati S, Tombolini V and Biagini C: Method of assessment of delayed damage in patients treated for Hodgkin's disease. Minutes of the XX AIRB Congress, 152-170, 1993.
19. Brusamolino E, Anselmo AP and Klersy C: The risk of acute leukemia in patients treated for Hodgkin's disease is significantly higher after combined modality programs than after chemotherapy alone and is correlated with the extent of radiotherapy and type and duration of chemotherapy: a case-control study. Haematologica 83: 812-823, 1998.
20. Brusamolino E, Lazzarino M and Orlandi E: Early stage Hodgkin's disease: long-term results with radiotherapy alone or combined radiotherapy and chemotherapy. Ann Oncol 5(2): 101-6, 1994.
21. Sont JK, Van Stiphout WHA and Noordijk EM: Increased risk of second cancers of managing Hodgkin's disease: the 20-year Leiden experience. Ann Haematol 65: 213-218, 1992.
22. Swerdlow AJ, Douglas AJ, Vaughan-Hudson B, Bennet MH and McLennan KA: Risk of second primary cancers after Hodgkin's disease by type of treatment: analysis of patients in the British National Lymphoma investigation. Br Med J 304: 1137-1143, 1992.
23. Van Leeuven FE, Klokman WJ and Hagenbeek A: Second cancer risk following Hodgkin's disease: a 20-year follow-up study. J Clin Oncol 12: 312-325, 1994.
24. Van Leeuven FE, Somers R and Taal BG: Increased risk of lung cancer, non-Hodgkin's lymphoma and leukaemia following Hodgkin's disease. J Clin Oncol 7: 1046-1058, 1989.
25. Maurizi Enrici R, Anselmo AP and Osti MF: Acute non-Lymphocytic Leukemia: onset after treatment for Hodgkin's disease. Ann Haematol 74: 103-110, 1997.
26. Anselmo AP, Cartoni C, Pacchiarotti A, Pescarmona E, Cafolla A and Rendina E: Peripheral neuroectodermal tumor of the chest (Askin tumor) as secondary neoplasm after Hodgkin's disease: a case report. Ann Haematol 68: 311-313, 1994.
27. Sieber M, Tesch H and Pfistner B: Rapidly alternating COPP/ABV/IMEP is not superior to conventional alternating COPP/ABVD in combination with extended field radiotherapy in intermediate stage Hodgkin's lymphoma: final results of the German Hodgkin's Lymphoma Study Group Trial HD5. J Clin Oncol 20(2): 476-484, 2002.
28. Zittoun R, Aidebert A and Hoerni B: Extended versus involved field irradiation combined with MOPP chemotherapy in early clinical stages Hodgkin's disease. J Clin Oncol 3(2): 207-14, 1985.
29. Santoro A, Bonfante V and Viviani S: Subtotal nodal versus involved field irradiation after 4 cycles of ABVD in early stage Hodgkin's disease. Proc Am Soc Clin Oncol 15: 415, 1996.
30. Loeffler M, Diehl V and Pfreundschuh M: Dose-response relationship of complementary radiotherapy following four cycles of combination chemotherapy in intermediate stage Hodgkin's disease. J Clin Oncol 15(6): 2275-87, 1997.
31. Gobbi GP, Cavalli C, Rossi A, Bertoloni D, Galeone F, Pieresca C and Grignani E: The role of dose and rate of administration of MOPP drugs in 97 retrospective Hodgkin's patients. Haematologica 72: 523-28, 1987.
32. De Vita VT: Dose-response is alive and well. J Clin Oncol 4(8): 1157-9, 1986.
33. Hryniuk WH and Levine MN: Analysis of dose intensity for adjuvant chemotherapy trials. J Clin Oncol 4: 162-1170, 1986.
34. Carde P, MacKintosh FR and Rosenberg SA: A dose and time response of the treatment of Hodgkin's disease with MOPP chemotherapy. J Clin Oncol 1(2): 146-53, 1983.
35. Longo DL, Young RC, Wesley M, Hubbard SM, Duffey PL, Jaffe ES and DeVita VT Jr: Twenty years of MOPP therapy for Hodgkin's disease. J Clin Oncol 4(9): 1295-306, 1986.